Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-06-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于调整2017年股票期权激励计划及相关文件中首次授予部分第三个行权期、预留授予部分第二个行权期及第三个行权期个人层面绩效考核要求的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding adjustments to the 2017 stock option incentive plan of the company. It discusses changes in performance assessment criteria for stock option exercise periods, approvals by the board and supervisory committee, independent director opinions, legal opinions, and financial advisor opinions. The content focuses on changes in management incentive plans and related governance matters rather than financial results or capital structure changes. It is not a full annual or interim report, nor an earnings release or capital update. It is also not a simple announcement of a report publication but a substantive disclosure of management decisions and governance related to stock option plans. This fits best under Board/Management Information (MANG), which covers announcements of changes in company management or board-related decisions, including incentive plan adjustments.
2020-06-22 Chinese
可转换公司债券之债券持有人会议规则（2020年6月）
Regulatory Filings Classification · 95% confidence The document is titled as rules for the bondholders' meeting of a convertible bond issued by the company. It extensively details the procedures, rights, obligations, and governance related to the bondholders' meetings, including voting rights, meeting convocations, and resolutions. There is no financial data, earnings information, or management discussion of financial results. It is a regulatory and procedural document related to bondholder meetings and governance of convertible bonds. This fits best under Regulatory Filings (RNS) as it is a compliance and procedural document that does not fit into other specific categories like Capital/Financing Update or Governance Information. The document length is substantial and contains detailed rules, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA). Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-06-22 Chinese
关于控股股东、实际控制人减持计划实施完毕暨减持股份累计达到1%的公告
Director's Dealing Classification · 95% confidence The document is a formal announcement from a company regarding the completion of a share reduction plan by its controlling shareholder and actual controller. It details the number of shares reduced, the dates, the methods of reduction, and the impact on shareholding percentages. The document includes tables showing shareholding before and after the reduction and confirms that the reduction plan has been fully implemented. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory disclosure about insider share transactions, specifically the reduction of shares by a major shareholder. This fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 4085 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the correct classification is DIRS with high confidence.
2020-06-05 Chinese
2020年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 second extraordinary general meeting of shareholders of the company. It includes voting results for multiple proposals, meeting attendance details, legal opinions from lawyers, and confirmation that the meeting and voting procedures complied with relevant laws and company regulations. The content focuses on the official results of shareholder votes on various matters, including issuance of convertible bonds and related arrangements. There is no indication that this is a full annual or interim report, audit report, or other financial report. The document is not a proxy solicitation or investor presentation but specifically reports the voting outcomes of a shareholders' meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2020-05-28 Chinese
2020年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed legal opinion and report on the convening, procedures, and voting results of a company's 2020 second extraordinary general meeting (临时股东大会). It includes extensive information on the meeting notice, attendees, voting procedures, and detailed voting results on multiple resolutions related to the issuance of convertible bonds and related matters. The document is not a financial report, earnings release, or management discussion but rather a formal legal opinion and detailed voting results announcement. It is not a brief announcement but a comprehensive report on the shareholder meeting and its resolutions. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official results from shareholder votes at a general meeting, including detailed vote counts and percentages for each agenda item.
2020-05-28 Chinese
关于取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (605 characters) from a company about receiving a medical device registration certificate from a regulatory authority. It includes details about the certificate, product, and impact on the company. There is no financial data, no mention of financial results, no meeting or voting information, no management changes, no legal proceedings, no capital changes, and no detailed report content. The document is an official regulatory announcement about a product registration, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a regulatory announcement about compliance and product registration. Given the short length and nature, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2020-05-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.